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Background: The role of cytomegalovirus (CMV) infection in triggering or exacerbating systemic 
lupus erythematosus (SLE) remains a subject of debate. The aim of this study was to compare the 
prevalence rate of CMV infection between individuals with and without SLE. 
Materials and Methods: This cross-sectional comparative study recruited 52 consecutive patients 
with SLE (based on the criteria determined by the Systemic Lupus Collaborating Clinics, 2012) and 
52 healthy subjects. The exclusion criteria were immunodeficiency and other background diseases. 
CMV infection was assessed according to serology (enzyme-linked immunosorbent assay) and 
polymerase chain reaction (PCR). 
Results: Immunoglobulin G (IgG) was positive in all participants. Immunoglobulin M (IgM) was 
positive in eight SLE patients (15.4%) and none of the controls (p = 0.003). The PCR was positive in 
four SLE patients (7.7%) and none of the controls (p = 0.041). IgM level was not related to age, 
gender, literacy, marital status, family history, SLE disease activity index (SLEDAI), or duration of 
the disease (p > 0.05). 
Conclusion: According to this study, CMV infection was higher in SLE patients but was not related 
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Introduction 
Systemic lupus erythematosus (SLE) is a 
rheumatologic disease leading to functional 
disability in 6.2% of cases (1). Like any other 
autoimmune disorder, the onset of SLE 
depends on both genetic and environmental 
factors. In recent decades, some researchers 
have suggested viral infections to be involved 
in the etiology of SLE. They also reported the 
potential of viruses to increase morbidity and 
mortality rates in patients with lupus (2-4). 
Recent evidence has highlighted the 
etiological role of retroviruses, such as human 
endogenous retroviruses (ERV), in the 
development of SLE (4,5). Some viruses, e.g. 
cytomegalovirus (CMV), Epstein-Barr virus 
(EBV), and parvovirus B19, have also been 
found to trigger the exacerbation of SLE 
(3,6,7). 
CMV infection has been linked with the risk of 
many autoimmune diseases such as multiple 
sclerosis (MS), SLE, systemic sclerosis, and 
rheumatoid arthritis (8). Several features of 
CMV, including its ability to manipulate 
adaptive and innate immune functions [9-12], 
large coding capacity [13], lytic replication in 
multiple tissues [14], and lifelong persistence 
during subsequent phases of latency and 
reactivation, along with its high prevalence in 
human populations, could explain its 
frequently identified association with not only 
some autoimmune disorders like SLE, but also 
further acquired disorders like arteriosclerosis 
[15], immune aging [16], and a few types of 
tumors [17]. Several reports have indicated the 
possible role of CMV infection in the onset or 
exacerbation of SLE, but have failed to clarify 
its exact role. Since the two diseases share 
similar manifestations, it is difficult to 
determine whether the symptoms are caused 
by CMV infection or the exacerbation of SLE. 
Despite the absence of definite evidence of the 
association between CMV and SLE, previous 
reports studies have suggested that CMV pp65 
subfragment peptide is highly immunogenic 
and can elicit the production of antibodies that 
cross-react with nuclear proteins and could be 
pathogenic in genetically susceptible 
individuals (18, 19). Therefore, this study was 
performed to compare the prevalence of CMV 
infection in individuals with and without SLE. 
Materials and Methods 
This cross-sectional comparative study 
recruited 52 consecutive SLE patients 
(diagnosed based on the criteria determined by 
the Systemic Lupus Collaborating Clinics, 
2012) who were referred to the rheumatology 
clinic of Hazrat-e-Rasoul Hospital and 52 
healthy individuals. The exclusion criteria 
were immunodeficiency and other background 
diseases. Age, gender, literacy, marital status, 
SLE disease activity index (SLEDAI), major 
organ involvement, type of treatment, and SLE 
duration were recorded in a specific form (20). 
The diagnosis of CMV infection was made by 
two methods, i.e. detection of anti-CMV 
antibodies by enzyme-linked immunosorbent 
assay (ELISA) and detection of CMV antigen 
by polymerase chain reaction (PCR), 
(Cytomegalovirus PCR Detection Kit, 
CinnaGen company, Iran).  
SLEDAI, a list of 24 clinical and laboratory 
items, was used for the measurement of 
disease activity. Helsinki Declaration was 
respected across the study and authors paid the 
costs. Chi-square and t test were applied for 
data analysis. All analyses were performed 
using SPSS 22.0 (SPSS Inc., Chicago, IL, 




The participants’ mean age was 36.63 ± 10.58 
years (range: 20-65 years) in the SLE group 
and 37.55 ± 12.42 years (range: 20-58 years) 
in the control group (p = 0.684). Females 
constituted 80.8% and 76.9% of the SLE and 
control groups, respectively (p = 0.631). 
Immunoglobulin G (IgG) was positive in all 
participants of both groups. Immunoglobulin 
M (IgM) was positive in eight SLE patients 
(15.4%) and none of the controls (p = 0.003). 
The PCR was positive in four SLE patients 
(7.7%) and none of the controls (p = 0.041). 
IgM level was not related to age, gender, 
literacy, marital status, family history, disease 
activity (SLEDAI), and duration of the disease 
(p > 0.05). The mean SLEDAI was 7.12 ± 5.86 
and 5.45 ± 4.32 in those with positive and 
negative IgM, respectively (p > 0.05). The 
mean disease duration was 5.37 ± 3.02 and 
6.28 ± 4.49 years in those with positive and 
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shown in Tables 1 and 2, neither the type of 
treatment nor the type of organ involvement 





A higher prevalence of CMV antibodies 
should be expected in SLE patients if CMV 
plays any causative role in the pathogenesis of 
SLE. Studies in different countries have 
yielded contradictory results in this regard. 
Compared to research in some other countries, 
European studies found a greater association 
between SLE and CMV seroprevalence (21-
25). 
In our study, IgG was positive in all 104 
participants but IgM was significantly higher 
in the SLE group. PCR detected CMV DNA in 
7.7% of the patients with SLE and none of the 
controls. The same finding was reported by 
some other studies. Rasmussen et al. found a 
higher rate of CMV infection in lupus patients 
(26). 
In 2007, Barazilia et al. observed elevated 
CMV IgG titers in the sera of SLE patients 
(27). Berkun et al. concluded that 
cytomegalovirus IgM and Epstein-Barr virus 
early antigen IgG (but not other Epstein-Barr 
virus antigens) were significantly more 
prevalent in SLE patients than in controls (28). 
In another report, percentage of patients with 
human CMV-DNA copy number > 2.0 x 10 
(2) copies/ml was higher than this copy 
number in controls which as statistically 
significant(29). Su et al. examined the serum 
samples of 87 patients with SLE and 97 
patients with cerebrovascular accidents (CVA) 
(30) and found the prevalence of anti-CMV 
IgM to be significantly higher in the SLE 
group than in the CVA group. In another 
study, PCR showed the presence of CMV and 
EBV DNA in respectively 30.3% and 51.5% 
of SLE patients (31). 
Contrary to the findings of the recent study, Su 
et al. showed that the severity of clinical 
features and SLEDAI scores were significantly 
higher in SLE patients with positive anti-CMV 
IgM compared to those with negative anti-
CMV IgM (30). Another study reported higher 
morbidity and mortality in SLE patients with 
positive CMV pp65 antigenemia assay (32). 
There are some reports about the relationship 
between CMV infection and the type of organ 
involvement in lupus patients. One study 
highlighted a relation between positive CMV 
and Raynaud’s phenomenon in lupus nephritis 
(33). Many case reports have also confirmed 
the association between CMV infection and 
hemophagocytic syndrome in lupus patients 
(34-36). Ramos-Casals et al. also reported 
CMV to be related to poor prognosis in 
patients with SLE (37). However, there were 
not any significant associations between CMV 
infection and type of organ involvement in our 
study. On the other hand, because of the 
similarity between lupus manifestations and 
CMV infection, it is difficult to determine 
whether the symptoms are due to CMV 
infection or the exacerbation of SLE. 
Some studies have reported acute CMV 
infections in SLE patients. In 2008, Ramos-
Casals et al. evaluated the impact of viral 
infections on the management on SLE patients 
and found 36 SLE patients who presented with 
organ-specific viral infections (mainly 
pneumonitis, colitis, retinitis, and hepatitis) 
(37) 
In 2011, Kelkar et al. described a case of CMV 
retinitis in a patient with SLE on 
immunosuppression. Immunosuppressive 
therapy seems to be the leading cause of CMV 
reactivation in lupus patients (38). 
Despite dissimilarities between the results 
of various studies, previous research 
generally confirms the link between lupus 
and CMV infection. Therefore, screening 
for CMV is suggested in all SLE patients. 




This open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial 3.0 (CC BY-NC 3.0). 
Downloaded from: www.jemerg.com	
F. Ferdowsi et al.  
rate and side effects of immunosuppressive 
drugs. Nevertheless, further studies with 
larger sample size and multi-center 
sampling are required to obtain more 
conclusive evidence. 
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